3SBio Inc. (HKG: 1530)

Market Cap	13.59B
Revenue (ttm)	9.05B
Net Income (ttm)	1.78B
Shares Out	2.36B
EPS (ttm)	0.73
PE Ratio	7.88
Forward PE	5.81
Dividend	0.25 (4.29%)
Ex-Dividend Date	Jul 22, 2024

Volume	9,821,626
Open	5.82
Previous Close	5.86
Day's Range	5.77 - 5.94
52-Week Range	4.91 - 7.85
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,411
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2023, 3SBio's revenue was 7.82 billion, an increase of 13.84% compared to the previous year's 6.87 billion. Earnings were 1.55 billion, a decrease of -19.13%.

Financial numbers in CNY